BEIJING, March 21,
2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc.
(NASDAQ: CASI) ("CASI" or the "Company"), a biopharmaceutical
company focused on developing and commercializing innovative
therapeutics and pharmaceutical products, today announced that the
redomiciliation merger to redomicile the Company as a Cayman Islands company (the "Redomiciliation
Merger") has been completed.
Pursuant to the Redomiciliation Merger, each outstanding share
of the common stock of the Company was converted into the right to
receive one ordinary share of CASI Pharmaceuticals, Inc., a company
incorporated under the laws of the Cayman
Islands ("CASI Cayman"). The ordinary shares of CASI Cayman
will be listed on the NASDAQ Capital Market under the trading
symbol "CASI," the same symbol under which the common stock of the
Company was listed.
About CASI Pharmaceuticals, Inc.
CASI Pharmaceuticals, Inc. is a biopharmaceutical company
focused on developing and commercializing innovative therapeutics
and pharmaceutical products in China, the United
States, and throughout the world. The Company is focused on
acquiring, developing, and commercializing products that augment
its hematology oncology therapeutic focus as well as other areas of
unmet medical need. The Company intends to execute its plan to
become a leader by launching medicines in the Greater China market, leveraging the Company's
China-based regulatory and
commercial competencies and its global drug development expertise.
The Company's operations in China
are conducted through its wholly-owned subsidiary, CASI
Pharmaceuticals (China) Co., Ltd.,
located in Beijing, China. More
information on CASI is available at
www.casipharmaceuticals.com.
Forward-Looking Statements
This news release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act with
respect to the outlook for expectations for future financial or
business performance, revenue growth, strategies, expectations, or
goals. Forward-looking statements are subject to numerous
assumptions, risks, and uncertainties, which change over time.
Forward-looking statements speak only as of the date they are made,
and we assume no duty to update forward-looking statements. New
factors emerge from time to time, and it is not possible for us to
predict which factors will arise. In addition, we cannot assess the
impact of each factor on our business or the extent to which any
factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking
statements. Actual results could differ materially from those
currently anticipated due to a number of factors.
For more information, please contact:
Company Contact:
CASI Pharmaceuticals, Inc.
Rui Zhang
240-864-2643
ir@casipharmaceuticals.co
View original content to download
multimedia:https://www.prnewswire.com/news-releases/casi-pharmaceuticals-completes-redomiciliation-merger-301777330.html
SOURCE CASI Pharmaceuticals, Inc.